AN URGENT TRACHEOTOMIA

No abstrac

Trends in pediatric epilepsy surgery in Europe between 2008 and 2015: Country‐, center‐, and age‐specific variation

OBJECTIVE: To profile European trends in pediatric epilepsy surgery (<16 years of age) between 2008 and 2015. METHODS: We collected information on volumes and types of surgery, pathology, and seizure outcome from 20 recognized epilepsy surgery reference centers in 10 European countries. RESULTS: We analyzed retrospective aggregate data on 1859 operations. The proportion of surgeries significantly increased over time (P < .0001). Engel class I outcome was achieved in 69.3% of children, with no significant improvement between 2008 and 2015. The proportion of histopathological findings consistent with glial scars significantly increased between the ages of 7 and 16 years (P for trend = .0033), whereas that of the remaining pathologies did not vary across ages. A significant increase in unilobar extratemporal surgeries (P for trend = .0047) and a significant decrease in unilobar temporal surgeries (P for trend = .0030) were observed between 2008 and 2015. Conversely, the proportion of multilobar surgeries and unrevealing magnetic resonance imaging cases remained unchanged. Invasive investigations significantly increased, especially stereo‐electroencephalography. We found different trends comparing centers starting their activity in the 1990s to those whose programs were developed in the past decade. Multivariate analysis revealed a significant variability of the proportion of the different pathologies and surgical approaches across countries, centers, and age groups between 2008 and 2015. SIGNIFICANCE: Between 2008 and 2015, we observed a significant increase in the volume of pediatric epilepsy surgeries, stability in the proportion of Engel class I outcomes, and a modest increment in complexity of the procedures

Options for Modelling the Financial Viability of Sofix Companies in the Post-Crisis Years

A financial crisis undoubtedly had the enormous negative operating on the real sector in a national and global scale. A grate number of stopping of companies, business restructuring, decrease of production, and staff surplus. Therefore it is vitally important to estimate financial steady development of the Bulgarian companies. Primary objective of such estimation - to identify accessible possibilities for the acceptance of the adequate, self-weighted decisions, to support companies in the process of adaptation to replacement of market requirements. Aim of the article - to foresee main financial pressures, using models for the estimation of authenticity of bankruptcy of companies and to offer the choice of decisions for overcoming these difficulties. An aim was arrived at through the empiric test of existent models in terms of open corporations of index of SO- FIX during four years, from 2011 to 2014. Results from this test then drawn on as a benchmark test in the process of decision-making.Фінансова криза поза сумнівом мала величезну негативну дію на реальний сектор в національному і глобальному масштабі, у вигляді числа припинень компаній, ділової реструктуризації, убування виробництва, і штабної надмірності. Тому життєво важливо оцінити фінансовий стійкий розвиток Болгарських компаній. Головна мета такої оцінки - ідентифікувати доступні можливості для ухвалення адекватних, зважених рішень, щоб підтримувати компанії в процесі пристосування до заміни ринкових вимог. Мета цієї статті - передбачити головні фінансові труднощі, використовуючи моделі для оцінки вірогідності банкрутства компаній і запропонувати вибір рішень для подолання ці труднощі. Мета досягалася через емпіричне випробування існуючих моделей в термінах відкритих акціонерних товариств індексу SOFIX впродовж чотирьох років, з 2011 до 2014. Результати від цього випробуванняпотім використані як еталонний тест в процесі ух- валення рішення.Финансовый кризис несомненно имел огромное негативное воздействие на реальный сектор в национальном и глобальном масштабе, в виде числа прекращений компаний, деловой реструктуризации, убывания производства, и штабной избыточности. Поэтому жизненно важно оценить финансовое устойчивое развитие Болгарских компаний. Главная цель такой оценки - идентифицировать доступные возможности для принятия адекватных, взвешенных решений, чтобы поддерживать компании в процессе приспосабливания к замене рыночных требований. Цель этой статьи - предсказать главные финансовые трудности, используя модели для оценки вероятностей банкротства компаний и предложить выбор решений для преодоления эти трудности. Цель достигалась через эмпирическое испытание существующих моделей в терминах открытых акционерных обществ индекса SOFIX в течение четырех лет, с 2011 до 2014. Результаты от этого испытания затем использованы как эталонный тест в процессе принятия решения

Proteogenomic characterization of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal pancreatic ductal tissues. Proteomic, phosphoproteomic, and glycoproteomic analyses were used to characterize proteins and their modifications. In addition, whole-genome sequencing, whole-exome sequencing, methylation, RNA sequencing (RNA-seq), and microRNA sequencing (miRNA-seq) were performed on the same tissues to facilitate an integrated proteogenomic analysis and determine the impact of genomic alterations on protein expression, signaling pathways, and post-translational modifications. To ensure robust downstream analyses, tumor neoplastic cellularity was assessed via multiple orthogonal strategies using molecular features and verified via pathological estimation of tumor cellularity based on histological review. This integrated proteogenomic characterization of PDAC will serve as a valuable resource for the community, paving the way for early detection and identification of novel therapeutic targets. [Display omitted] •Proteogenomic characterization reveals the functional impact of genomic alterations•Phosphoproteomics uncovers putative therapeutic targets downstream of KRAS•Multiomics links endothelial cell remodeling and glycolysis to immune exclusion•Proteomics and glycoproteomics reveal candidates for early detection or intervention Comparative multiomic analyses of pancreatic ductal adenocarcinoma tumors with normal adjacent and pancreatic ductal tissues provide insight into genomic, proteomic, and immune dysregulation in driving disease

Proteogenomic and metabolomic characterization of human glioblastoma

Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its molecular pathogenesis is crucial to improving diagnosis and treatment. Integrated analysis of genomic, proteomic, post-translational modification and metabolomic data on 99 treatment-naive GBMs provides insights to GBM biology. We identify key phosphorylation events (e.g., phosphorylated PTPN11 and PLCG1) as potential switches mediating oncogenic pathway activation, as well as potential targets for EGFR-, TP53-, and RB1-altered tumors. Immune subtypes with distinct immune cell types are discovered using bulk omics methodologies, validated by snRNA-seq, and correlated with specific expression and histone acetylation patterns. Histone H2B acetylation in classical-like and immune-low GBM is driven largely by BRDs, CREBBP, and EP300. Integrated metabolomic and proteomic data identify specific lipid distributions across subtypes and distinct global metabolic changes in IDH-mutated tumors. This work highlights biological relationships that could contribute to stratification of GBM patients for more effective treatment. Wang et al. perform integrated proteogenomic analysis of adult glioblastoma (GBM), including metabolomics, lipidomics, and single nuclei RNA-Seq, revealing insights into the immune landscape of GBM, cell-specific nature of EMT signatures, histone acetylation in classical GBM, and the existence of signaling hubs which could provide therapeutic vulnerabilities